Research peptide · LY3298176
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
| Molecule | Tirzepatide (LY3298176, dual agonist) |
| Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(palmitoyl-gamma-Glu-AEEA-AEEA)-Ile-Ala-Gln-Ala-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Form | Lyophilized powder |
| Strength per vial | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 90 mg, 100 mg |
| Box contents | 10 vials of identical strength |
| Purity | ≥99 % (HPLC) |
Tirzepatide is a dual agonist at the GIP and GLP-1 receptors. Both incretin pathways influence glucose handling and energy balance, and in vitro models are used to study receptor binding, signal transduction and the downstream metabolic routes. As a reference ligand, the compound allows direct comparison of the activation of both receptor classes in controlled assay systems, with all findings interpreted strictly within the respective experimental design. Researchers who buy Tirzepatide use this 10-vial kit as a defined reference for in-vitro work.
The lyophilized powder is reconstituted in the laboratory with a suitable sterile solvent. The resulting solution is processed promptly and protected from direct light. Standard laboratory practice applies when handling the powder and the solution: a clean work surface, suitable protective equipment and a documented procedure. Volume or concentration figures are not part of this specification; the choice of solvent and preparation scheme follows the protocol of the receiving institution.
Tirzepatide is used as a reference ligand in in vitro assays, including GIP/GLP-1 receptor and incretin signalling studies. Typical readouts cover binding kinetics, cAMP accumulation and downstream signalling in cell-based models. The compound supports the methodological comparison of dual versus selective receptor activation and helps characterise assay systems. All work is performed in vitro by qualified laboratories within their own research programmes.
Every lot is analysed by HPLC for purity and meets ≥99 %. The identity of the lipidated peptide sequence is confirmed as well. The measured values are documented per lot, and release follows review against the defined specification. These checks apply uniformly to all offered strengths and refer to the lyophilized powder before reconstitution.
Available amounts per vial: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 90 mg, 100 mg. Box of 10 vials.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
A box contains exactly 10 identical, unlabelled vials of the selected variant. The product label is on the outer box.
Available amounts per vial: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 90 mg, 100 mg.
5-Amino-1MQ
AHK-Cu
AOD-9604
B12
BAC Water 10 ml
BPC-157
Cagrilintide 5 mg
CJC-1295 (Mod GRF 1-29)
